Pfizer licenses therapy for autoimmune diseases

Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived from human blood plasma.

Pfizer is licensing a pre-clinical therapy for patients with rare autoimmune conditions, paying $25 million upfront for what the company sees as a potentially better alternative to a treatment derived from human blood plasma.

The big drug maker signed an exclusive global licensing deal with Baltimore, Maryland-based startup Gliknik for the drug candidate stradomer,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category